BioInsights - An educated approach: AI-enabled neoantigen vaccine R&D

An educated approach: AI-enabled neoantigen vaccine R&D

Cell & Gene Therapy Insights 2020; 6(4), 591–595

10.18609/cgti.2020.069

Published: 14 May 2020
Interview
Roman Yelensky

Roman Yelensky is Gritstone Oncology’s first employee and serves as chief technology officer, with responsibility for the EDGE tumor antigen identification platform. Previously, Dr Yelensky was vice president at Foundation Medicine, which he joined at its inception. At Foundation Medicine, he co-led sequence data analysis for FoundationOne and led validation studies supporting clinical laboratory accreditation and testing of more than 100,000 patients. Dr Yelensky established Foundation Medicine’s FDA-regulated products program, leading to FDA approval of the first NGS-based companion diagnostic. He holds a PhD in bioinformatics and genomics from the Massachusetts Institute of Technology and has co-authored more than 75 manuscripts, including most recently on EDGE in Nature Biotechnology.